When a 52-year-old teacher from Utrecht received a letter summoning her back for additional mammogram views, she assumed it was a routine precaution. She had no family history of breast cancer and felt perfectly healthy. But the next six weeks brought two more appointments, a needle biopsy, and a diagnosis of benign breast tissue. “Every time the phone rang, I thought it was the hospital calling with bad news,” she recalls. “I couldn't sleep. I kept imagining my children growing up without me.” Her experience is far from unusual in the Netherlands, where the national breast cancer screening program recalls roughly 9 to 11 percent of women each year — one of the highest recall rates in Europe.

A Routine Mammogram Turned into Months of Uncertainty

The Dutch screening program invites women aged 50 to 75 for mammography every two years. In 2023, over 1.2 million women participated. Of those, approximately 110,000 received a recall letter requesting additional imaging or a clinical examination. For the vast majority — about 80 percent — the suspicious finding turned out to be benign. But the wait for final clearance can stretch weeks, and the emotional toll is immediate.

“The moment you see that envelope, your heart drops,” says Liesbeth de Wit, a 58-year-old from Amsterdam who had a false positive in 2022. De Wit underwent a core needle biopsy that left a small scar and weeks of soreness. “The radiologist said it was probably nothing, but ‘probably’ didn't help me sleep.” Her story echoes across online forums and patient surveys, where women describe panic, disrupted work, and strained relationships during the diagnostic workup. The teacher from Utrecht echoes similar sentiments: “Every time the phone rang, I thought it was the hospital calling with bad news. I couldn't sleep. I kept imagining my children growing up without me.” Both women, though unrelated, illustrate a common pattern: the interval between recall and final diagnosis is a period of intense distress, regardless of the eventual outcome.

Radiologists acknowledge the distress but frame it as an acceptable price for catching cancers early. The Dutch Radiology Society's guidelines explicitly accept recall rates up to 12 percent, arguing that the alternative — missing a small tumor — carries far graver consequences. “A few weeks of anxiety is not nothing, but it is temporary,” says Dr. Henk van der Veen, a breast radiologist at the Netherlands Cancer Institute. “We weigh that against a woman's chance of dying from breast cancer.”

The tension between population-level benefit and individual distress is not unique to the Netherlands, but it is particularly acute here. The Dutch program detects roughly 17,000 cancers annually, and about 80 percent of screen-detected breast cancers are early-stage, with a five-year survival rate above 95 percent. Yet for every cancer found, roughly six women are recalled and cleared. Critics ask: at what point does the net benefit begin to fray?

The Numbers Behind the Dutch Recall Rate

To understand why the Netherlands recalls so many women, one must look at the screening protocol. Unlike the United Kingdom, where a single radiologist reads each mammogram, the Netherlands mandates double reading by two independent radiologists. If either flags an abnormality, the woman is recalled. This practice boosts sensitivity — the ability to detect cancer — but inevitably increases false positives.

Data from the Dutch National Evaluation Team for Breast Cancer Screening show that the recall rate has crept upward over the past decade, from about 8 percent in 2013 to nearly 11 percent in 2023. Some of this rise may reflect the introduction of digital mammography, which produces higher-resolution images but also highlights more benign findings such as calcifications or dense tissue. “Digital mammography is a victim of its own success,” says Dr. Anouk van der Waal, a radiologist at Maastricht University Medical Center. “We see more, but we can't always tell what is significant.”

By comparison, the UK's National Health Service recalls roughly 5 percent of screened women, and Sweden's rate hovers around 3 to 4 percent. The difference is partly explained by age thresholds: the Netherlands begins screening at age 50, while the UK starts at 50 and Sweden at 40. But even among women aged 50–69, Dutch recall rates are higher. A 2021 study in the European Journal of Cancer (van der Waal et al.) found that the Netherlands had a cumulative false-positive risk of roughly 20 percent after 10 screens — meaning one in five women will experience at least one false positive over a decade of biennial screening.

Radiologists defend the threshold by pointing to interval cancers — tumors that appear between screens, often aggressive and missed by mammography. The Dutch interval cancer rate is among the lowest in Europe, at about 1.1 per 1,000 screened women per year, compared to roughly 1.8 in the UK. “We catch more cancers early, and fewer women present with advanced disease between screens,” van der Veen argues. “That is not a coincidence.” But the trade-off is clear: more false positives.

How Radiologists Justify the Current Threshold

For radiologists, the calculus is rooted in the fundamental goal of screening: reduce breast cancer mortality. A 2024 systematic review in The Lancet estimated that mammography screening reduces breast cancer deaths by about 20 percent among invited women. The Dutch program achieves this in part by erring on the side of caution. “If I have a 95 percent certainty that a finding is benign, I still recall that woman,” says van der Waal. “My job is not to be efficient; it is to not miss a cancer.”

Professional guidelines reinforce this mindset. The Dutch Radiology Society's quality standards, updated in 2022, set a target recall rate of 8 to 12 percent for first screens and 4 to 8 percent for subsequent screens. Programs falling below these thresholds are flagged for possible underdiagnosis. “There is a cultural belief that lower recall means lower quality,” notes Dr. Sophie de Koning, a health services researcher at the University of Amsterdam who studies screening outcomes.

Radiologists also point to evidence that false positives rarely lead to unnecessary treatment. A 2019 Dutch cohort study of over 200,000 women (de Gelder et al., International Journal of Cancer) found that only 0.1 percent of false-positive recalls resulted in a biopsy that showed high-risk lesions requiring surgery or chemoprevention. “We are not over-treating these women,” van der Veen insists. “We are over-investigating, temporarily.” Studies on long-term psychological harm are mixed, but a 2019 analysis from the Rotterdam screening region found that anxiety and depression scores returned to baseline within six months after a false-positive result, except among women with pre-existing health anxiety.

Yet the same study noted that about 15 percent of women reported lingering worry at one-year follow-up, and some avoided subsequent screening. “Short-term distress is one thing,” says de Koning. “But if women drop out of the program, the benefit of screening is lost for them.”

Patient Advocacy Groups Push Back

Patient organizations argue that the radiologists' perspective minimizes the real-world impact. The Dutch Breast Cancer Association (Borstkanker Vereniging Nederland) conducted a survey in 2023 of over 1,200 women who had experienced a false positive. More than half reported that the experience made them “more anxious” about breast cancer, and one in five said they considered skipping future mammograms. “We are told to be grateful that our cancer was ruled out, but the fear doesn't disappear overnight,” says association director Margriet van der Heijden (no relation to the teacher).

Advocates are pushing for shared decision-making before a woman even enters the screening van. They want a clear explanation of the false-positive risk — ideally personalized based on age, breast density, and family history — so women can make an informed choice about whether to participate. “Right now, the invitation letter says you are called for a screening mammogram. It does not say that one in ten women will be called back for nothing,” van der Heijden notes.

Some propose that recall rates should be published per screening center, creating transparency that could drive improvement. Currently, the Dutch National Institute for Public Health and the Environment (RIVM) releases national aggregate data but does not disclose center-level variation. A 2022 audit by the Dutch Health Inspectorate found that recall rates ranged from 7 percent to 14 percent across regions, without clear correlation with cancer detection rates. “That variation suggests some centers are overcalling,” says de Koning. “We need to understand why.”

Another avenue is risk-based screening, where women with denser breasts or other risk factors are screened more frequently or with supplemental imaging, while those at lower risk are recalled less often. Pilot programs in the Netherlands are testing this approach, but widespread implementation remains years away.

What the Evidence Says About Psychological Harm

The research on psychological consequences of false-positive mammograms is extensive but not conclusive. A 2020 meta-analysis in BMJ pooled 28 studies and found that women who experienced a false positive reported significantly higher anxiety and breast cancer-specific distress up to 12 months after the event, compared to women with normal screens. The effect size was moderate, but it persisted even after diagnostic resolution.

Physiological responses are also documented. A 2022 Dutch study measured salivary cortisol — a stress hormone — in women immediately after receiving a recall letter and again after their follow-up appointment. Cortisol levels were elevated at the first measurement and dropped after clearance, but remained higher than baseline in women with high health anxiety. “The body registers this as a threat, even if the mind knows the outcome is benign,” says Dr. Ineke van der Molen, a health psychologist at Tilburg University.

However, the same meta-analysis found no consistent link between false positives and clinical depression or post-traumatic stress disorder. Most women recover, and some even report a sense of relief that heightens their vigilance. “It is not that false positives are harmless, but they are not catastrophic for the majority,” van der Molen says. “The challenge is identifying the minority who will suffer long-term.”

Quality-of-life measures during the diagnostic workup show clear dips. A 2021 study using the EQ-5D questionnaire found that women awaiting biopsy reported lower scores on mobility, usual activities, and anxiety/depression than the general population. Once cleared, scores rebounded, but the temporary impairment is real. “We need to weigh that temporary dip against the years of life saved from early detection,” says de Koning. “It is not an easy balance.”

Comparing False Positive Policies Across Europe

The Netherlands is not the only country with a high recall rate, but it stands out among its peers. In the United Kingdom, the NHS Breast Screening Programme recalled about 5 percent of women in 2022–2023, with a cancer detection rate of roughly 8 per 1,000 screened. Sweden, which uses double reading like the Netherlands, recalls around 3 to 4 percent, partly because Swedish radiologists accept higher mammographic density thresholds before calling a finding suspicious.

Italy and Germany also employ double reading and report recall rates around 8 percent, though regional variation is wide. Denmark shifted from annual to biennial screening in 2010 and simultaneously adopted a stricter recall threshold; its recall rate dropped from 6 percent to under 4 percent without a detectable increase in interval cancers, according to a 2018 evaluation. “Denmark showed that you can lower false positives without harming the program,” says van der Waal. “But their population may be different — lower breast density on average.”

The European Commission's 2022 guidelines on cancer screening recommend that recall rates should not exceed 10 percent for first screens and 5 percent for subsequent screens, but these are non-binding. Each country's health technology assessment body sets its own standards. “There is no European consensus because the trade-off between sensitivity and specificity is a value judgment,” says de Koning. “It depends on how much anxiety a society is willing to accept.”

Some countries have experimented with alternative technologies. Digital breast tomosynthesis (3D mammography) can reduce false positives by 15 to 30 percent by allowing radiologists to see through overlapping tissue. The Netherlands is gradually introducing tomosynthesis, but cost and training barriers slow adoption. “Tomosynthesis is not a magic bullet, but it helps,” van der Veen says. “We are moving in that direction.”

What Could Change in Dutch Screening Practice

Several promising innovations could reshape the balance between sensitivity and false positives. Artificial intelligence (AI) software that triages mammograms is being tested in multiple Dutch screening centers. Early results from a 2024 pilot at the University Medical Center Utrecht suggest that AI can reduce recall rates by about 20 percent while maintaining cancer detection, by flagging only high-suspicion findings for double reading. “AI can learn to ignore the benign calcifications that human eyes tend to call equivocal,” explains Dr. Jeroen van den Berg, a radiologist leading the pilot.

Personalized screening intervals are another avenue. A large European trial called PROCAS (Predicting Risk of Cancer at Screening) is using risk models based on breast density, genetic markers, and lifestyle factors to assign women to annual, biennial, or triennial screening. In the Netherlands, a subset of women with extremely dense breasts is being offered supplemental MRI, which is highly sensitive but also expensive and prone to its own false positives. “We cannot apply a one-size-fits-all approach and expect everyone to accept the same recall risk,” says van der Heijden of the patient association.

Structural changes are also under discussion. Some centers now offer on-the-spot ultrasound after an abnormal mammogram, allowing women to receive immediate results rather than waiting days for a separate appointment. A 2023 study in the Netherlands Journal of Radiology found that same-day assessment reduced anxiety scores by half compared to delayed workup. “The waiting is the worst part,” says van der Molen. “If we can shorten that, we reduce harm.”

In 2027, the Dutch National Health Council is expected to review the screening program's quality benchmarks, including the acceptable recall rate. Patient advocates hope the review will lead to lower targets, while radiologists caution against overcorrection. “We must not lose sight of the main goal: saving lives,” van der Veen says. “But we also need to listen to the women who are frightened by the system designed to protect them.”

Broader Implications and Unanswered Questions

The debate over false positives in the Netherlands reflects a wider tension in public health: how much harm is acceptable in the pursuit of benefit? Screening programs are designed for populations, not individuals, and their success is measured in mortality reduction, not patient experience. But as patient advocacy grows more vocal, policymakers are beginning to reconsider the metrics that define quality.

One unanswered question is whether the psychological cost of false positives is distributed equitably. Women with lower health literacy or limited social support may experience greater distress, yet screening programs rarely account for these factors. A 2023 qualitative study from the University of Groningen found that women from immigrant backgrounds were more likely to report confusion and fear after a recall, partly due to language barriers in follow-up communication. “We need to ensure that the entire pathway — from invitation to diagnosis — is accessible and supportive,” says de Koning.

Another issue is the potential for overdiagnosis: the detection of cancers that would never have caused symptoms or death. Estimates vary, but a 2023 analysis in the New England Journal of Medicine suggested that overdiagnosis accounts for 10 to 20 percent of screen-detected breast cancers in high-income countries. While the Dutch program's low interval cancer rate suggests it catches many clinically significant tumors, some radiologists privately acknowledge that a small fraction of detected cancers may be indolent. “We cannot always tell which ones will progress,” van der Veen admits. “That uncertainty is inherent in screening.”

For women like the teacher from Utrecht and Liesbeth de Wit, the debate is not abstract. They carry the memory of those weeks of fear, even as they acknowledge the program's benefits. “I still go for screening,” de Wit says. “But every time I see that envelope, my heart races. I don't think that will ever go away.”